David P. Dearnaley

David P. Dearnaley

London, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 301 publications

Targeted Prostate Cancer Screening in Carriers of BRCA1 or BRCA2 Pathogenic Germline Variants Detects Clinically Relevant Disease: 5-year Results from the IMPACT Study.

Targeted Prostate Cancer Screening in Carriers of BRCA1 or BRCA2 Pathogenic Germline Variants Detects Clinically Relevant Disease: 5-year Results from the IMPACT Study.

Journal: European urology

Published: October 23, 2025

International Multidisciplinary Consensus Group for Malignant Spinal Cord Compression: recommendations for definitions, reporting items, and study endpoints for clinical trials and audits.

International Multidisciplinary Consensus Group for Malignant Spinal Cord Compression: recommendations for definitions, reporting items, and study endpoints for clinical trials and audits.

Journal: The Lancet. Oncology

Published: August 06, 2025

Correlation of Biochemical Recurrence With Adverse Late Toxic Events Following Prostate Radiation Therapy (COBALT Study): An Individual Patient Data Meta-Analysis of 7 Randomized Trials.

Correlation of Biochemical Recurrence With Adverse Late Toxic Events Following Prostate Radiation Therapy (COBALT Study): An Individual Patient Data Meta-Analysis of 7 Randomized Trials.

Journal: International journal of radiation oncology, biology, physics

Published: July 09, 2025

Correlation of Biochemical Recurrence with Adverse Late Toxic Events Following Prostate Radiotherapy (COBALT Study): An Individual Patient Data Meta-Analysis of 7 Randomized Trials.

Correlation of Biochemical Recurrence with Adverse Late Toxic Events Following Prostate Radiotherapy (COBALT Study): An Individual Patient Data Meta-Analysis of 7 Randomized Trials.

Journal: International journal of radiation oncology, biology, physics

Published: July 09, 2025

Moderate hypofractionated radiotherapy for localised prostate cancer: A new standard of care.

Moderate hypofractionated radiotherapy for localised prostate cancer: A new standard of care.

Journal: Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique

Published: May 28, 2025

Metformin for patients with metastatic prostate cancer starting androgen deprivation therapy: a randomised phase 3 trial of the STAMPEDE platform protocol.

Metformin for patients with metastatic prostate cancer starting androgen deprivation therapy: a randomised phase 3 trial of the STAMPEDE platform protocol.

Journal: The Lancet. Oncology

Published: March 13, 2025

Hypofractionated radiotherapy for prostate cancer (HYDRA): an individual patient data meta-analysis of randomised trials in the MARCAP consortium.

Hypofractionated radiotherapy for prostate cancer (HYDRA): an individual patient data meta-analysis of randomised trials in the MARCAP consortium.

Journal: The Lancet. Oncology

Published: December 06, 2024

The interplay between acute and late toxicity among patients receiving prostate radiotherapy: an individual patient data meta-analysis of six randomised trials.

The interplay between acute and late toxicity among patients receiving prostate radiotherapy: an individual patient data meta-analysis of six randomised trials.

Journal: The Lancet. Oncology

Published: October 25, 2024

Radiation-induced lymphocyte apoptosis and chromosomic aberrations for prediction of toxicities in patients undergoing radical radiotherapy for breast or prostate cancers.

Radiation-induced lymphocyte apoptosis and chromosomic aberrations for prediction of toxicities in patients undergoing radical radiotherapy for breast or prostate cancers.

Journal: The British journal of radiology

Published: July 28, 2024

Reply to J.A. Garcia et al.

Reply to J.A. Garcia et al.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: June 14, 2024

Prognostic Impact of Prostate-Specific Antigen at 6 Months After Radiotherapy in Localized Prostate Cancer: An Individual Patient Data Analysis of Randomized Trials.

Prognostic Impact of Prostate-Specific Antigen at 6 Months After Radiotherapy in Localized Prostate Cancer: An Individual Patient Data Analysis of Randomized Trials.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: March 12, 2024

Weekly ultra-hypofractionated radiotherapy in localised prostate cancer.

Weekly ultra-hypofractionated radiotherapy in localised prostate cancer.

Journal: Clinical and translational radiation oncology

Published: January 19, 2024

Showing 1-12 of 301

Last Updated: 09/26/2026